ADXN | Addex Therapeutics Ltd Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	9.50 - 10.40
52 Week Range	5.00 - 27.90
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	61,909
Average Volume	286,725
Shares Outstanding	1,592,615
Market Cap	16,085,412
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-02-12

Valuation
Profitability
Growth
Health
P/E Ratio	-0.51
Forward P/E Ratio	N/A
EPS	-19.70
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	23
Country	Switzerland
Website	ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

ADXN's peers: IPHA, APM, CYAD, DYAI, ACGN, ERYP, SNGX, ATXI, KRON, CYCN, LRMR, ACHL, APVO, CELZ, IMRN

*Chart delayed

Analyzing fundamentals for ADXN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ADXN Fundamentals page.

Watching at ADXN technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on ADXN Technicals page.